DK54390A - Okularcyklosporinpraeparat - Google Patents

Okularcyklosporinpraeparat Download PDF

Info

Publication number: DK54390A
Authority: DK; Denmark
Prior art keywords: cyclosporine; enhance; corn oil; ocular; agents
Prior art date: 1987-09-03

Application number

DK054390A

Other languages

English (en)

Other versions

DK54390D0 (da

Inventor

Renee Kaswan

Original Assignee

Univ Georgia Res Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-09-03

Filing date

1990-03-01

Publication date

1990-05-03

1987-09-03 Priority claimed from US07/092,466 external-priority patent/US4839342A/en

1990-03-01 Application filed by Univ Georgia Res Found filed Critical Univ Georgia Res Found

1990-03-01 Publication of DK54390D0 publication Critical patent/DK54390D0/da

1990-05-03 Publication of DK54390A publication Critical patent/DK54390A/da

Links

PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title abstract 4
108010036949 Cyclosporine Proteins 0.000 title abstract 4
229960001265 ciclosporin Drugs 0.000 title abstract 4
229930182912 cyclosporin Natural products 0.000 title abstract 4
239000000203 mixture Substances 0.000 abstract 3
239000002285 corn oil Substances 0.000 abstract 2
235000005687 corn oil Nutrition 0.000 abstract 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 abstract 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract 2
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 abstract 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 1
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 abstract 1
229960004308 acetylcysteine Drugs 0.000 abstract 1
229940087168 alpha tocopherol Drugs 0.000 abstract 1
239000003242 anti bacterial agent Substances 0.000 abstract 1
239000002260 anti-inflammatory agent Substances 0.000 abstract 1
229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
229940088710 antibiotic agent Drugs 0.000 abstract 1
229940121375 antifungal agent Drugs 0.000 abstract 1
-1 antifungals Substances 0.000 abstract 1
239000003963 antioxidant agent Substances 0.000 abstract 1
235000006708 antioxidants Nutrition 0.000 abstract 1
239000003443 antiviral agent Substances 0.000 abstract 1
229940121357 antivirals Drugs 0.000 abstract 1
OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 abstract 1
229960003870 bromhexine Drugs 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003246 corticosteroid Substances 0.000 abstract 1
229960001334 corticosteroids Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000003172 expectorant agent Substances 0.000 abstract 1
230000035876 healing Effects 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
239000000314 lubricant Substances 0.000 abstract 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 abstract 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 abstract 1
229960002216 methylparaben Drugs 0.000 abstract 1
229940066491 mucolytics Drugs 0.000 abstract 1
229960001416 pilocarpine Drugs 0.000 abstract 1
239000003755 preservative agent Substances 0.000 abstract 1
239000004094 surface-active agent Substances 0.000 abstract 1
230000004489 tear production Effects 0.000 abstract 1
229960000984 tocofersolan Drugs 0.000 abstract 1
230000000699 topical effect Effects 0.000 abstract 1
239000005526 vasoconstrictor agent Substances 0.000 abstract 1
239000000080 wetting agent Substances 0.000 abstract 1
239000002076 α-tocopherol Substances 0.000 abstract 1
235000004835 α-tocopherol Nutrition 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

DK054390A 1987-09-03 1990-03-01 Okularcyklosporinpraeparat DK54390A (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US07/092,466 US4839342A (en)	1987-09-03	1987-09-03	Method of increasing tear production by topical administration of cyclosporin
US11721887A	1987-11-04	1987-11-04
US18782388A	1988-04-29	1988-04-29
PCT/US1988/003039 WO1989001772A1 (en)	1987-09-03	1988-08-31	Ocular cyclosporin composition

Publications (2)

Publication Number	Publication Date
DK54390D0 DK54390D0 (da)	1990-03-01
DK54390A true DK54390A (da)	1990-05-03

Family

ID=27377210

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK054390A DK54390A (da)	1987-09-03	1990-03-01	Okularcyklosporinpraeparat

Country Status (12)

Country	Link
US (1)	US5411952A (da)
EP (1)	EP0391909B1 (da)
JP (1)	JPH0667850B2 (da)
KR (1)	KR920003601B1 (da)
AT (1)	ATE109970T1 (da)
DE (1)	DE3851152T2 (da)
DK (1)	DK54390A (da)
ES (1)	ES2012116A6 (da)
GR (1)	GR1000558B (da)
IE (1)	IE65582B1 (da)
PH (1)	PH24814A (da)
WO (1)	WO1989001772A1 (da)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5540931A (en) *	1989-03-03	1996-07-30	Charles W. Hewitt	Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4996193A (en) *	1989-03-03	1991-02-26	The Regents Of The University Of California	Combined topical and systemic method of administration of cyclosporine
CA1340994C (en) *	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Treatment of conditions and disease
ZA927277B (en) *	1991-10-02	1993-05-19	Boston Ocular Res	Dry eye treatment process and solution.
DE69307505T2 (de)	1992-05-13	1997-07-24	Sandoz-Patent-Gmbh, 79539 Loerrach	Opthalmische zusammensetzungen enthaltend ein cyclosporin
US5366739A (en) *	1992-08-06	1994-11-22	Deo Corporation	Method of ophthalmic drug delivery
US5830508A (en)	1992-08-06	1998-11-03	Deo Corporation	Composition for treating dry eye
US5686436A (en)	1993-05-13	1997-11-11	Hiv Diagnostics, Inc.	Multi-faceted method to repress reproduction of latent viruses in humans and animals
US5474979A (en) *	1994-05-17	1995-12-12	Allergan, Inc.	Nonirritating emulsions for sensitive tissue
IE75744B1 (en) *	1995-04-03	1997-09-24	Elan Corp Plc	Controlled release biodegradable micro- and nanospheres containing cyclosporin
US5869079A (en) *	1995-06-02	1999-02-09	Oculex Pharmaceuticals, Inc.	Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5858401A (en) *	1996-01-22	1999-01-12	Sidmak Laboratories, Inc.	Pharmaceutical composition for cyclosporines
WO1997029776A1 (en)	1996-02-13	1997-08-21	G.D. Searle & Co.	Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
AU1952597A (en)	1996-02-13	1997-09-02	G.D. Searle & Co.	Combinations, having immunosuppressive effects, containing cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
JP2000506170A (ja) *	1996-03-05	2000-05-23	メデイノックス，インコーポレイテッド	酸化窒素スキャベンジャーを用いる複合治療方法とそのために有用な組成物
US20030220234A1 (en) *	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
EP0991660B8 (en)	1997-10-08	2006-04-05	Isotechnika,Inc.	DEUTERATED and undeuterated CYCLOSPORINE ANALOGS AND THEIR USE AS IMMUNOMODULATING AGENTS
US6861411B1 (en)	1997-12-02	2005-03-01	Pfizer, Inc.	Method of treating eye infections with azithromycin
US5981607A (en) *	1998-01-20	1999-11-09	Allergan	Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
GB9818278D0 (en) *	1998-08-22	1998-10-14	Smith & Nephew	Compositions
US6217895B1 (en) *	1999-03-22	2001-04-17	Control Delivery Systems	Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20040121014A1 (en) *	1999-03-22	2004-06-24	Control Delivery Systems, Inc.	Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6239113B1 (en)	1999-03-31	2001-05-29	Insite Vision, Incorporated	Topical treatment or prevention of ocular infections
US7056893B2 (en)	1999-03-31	2006-06-06	Insite Vision, Inc.	Topical treatment for prevention of ocular infections
US6255280B1 (en)	1999-04-08	2001-07-03	University Of Kentucky Research Foundation	Protection against traumatic brain injury
US6254860B1 (en) *	1999-04-13	2001-07-03	Allergan Sales, Inc.	Ocular treatment using cyclosporin-A derivatives
BRPI0014869B8 (pt) *	1999-10-15	2021-05-25	Sucampo Ag	prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização
EP1142566B1 (fr)	2000-04-07	2003-10-01	Laboratoire Medidom S.A.	Formulations ophtalmiques à base de ciclosporine, d'acide hyaluronique et du polysorbate
US6375972B1 (en)	2000-04-26	2002-04-23	Control Delivery Systems, Inc.	Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20030021816A1 (en) *	2001-06-06	2003-01-30	Sewon Kang	Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
US7141648B2 (en)	2001-10-19	2006-11-28	Isotechnika Inc.	Synthesis of cyclosporin analogs
KR20030065831A (ko) *	2002-02-01	2003-08-09	주식회사 태평양	사이클로스포린을 함유한 지속 방출형 약학적 조성물
US8871241B2 (en)	2002-05-07	2014-10-28	Psivida Us, Inc.	Injectable sustained release delivery devices
US6930127B2 (en) *	2002-08-15	2005-08-16	Eaton Veterinary Laboratories, Inc.	Veterinary treatment of ophthalmic disease in animals using topical tacrolimus
US7354574B2 (en)	2002-11-07	2008-04-08	Advanced Ocular Systems Limited	Treatment of ocular disease
EP1603512A2 (en) *	2003-03-17	2005-12-14	Albany Molecular Research, Inc.	Novel cyclosporins
US20040185068A1 (en) *	2003-03-18	2004-09-23	Zhi-Jian Yu	Self-emulsifying compositions, methods of use and preparation
CA2520660C (en) *	2003-03-28	2013-08-20	Sigmoid Biotechnologies Limited	Solid oral dosage form containing seamless microcapsules
US7083802B2 (en)	2003-07-31	2006-08-01	Advanced Ocular Systems Limited	Treatment of ocular disease
US20050059583A1 (en)	2003-09-15	2005-03-17	Allergan, Inc.	Methods of providing therapeutic effects using cyclosporin components
CA2539324A1 (en)	2003-09-18	2005-03-31	Macusight, Inc.	Transscleral delivery
US7083803B2 (en)	2003-09-19	2006-08-01	Advanced Ocular Systems Limited	Ocular solutions
US7087237B2 (en)	2003-09-19	2006-08-08	Advanced Ocular Systems Limited	Ocular solutions
EP1706095B1 (en)	2004-01-20	2008-12-24	Allergan, Inc.	Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7923471B2 (en) *	2004-05-14	2011-04-12	Alcon, Inc.	Method of treating dry eye disorders and uveitis
US20050277584A1 (en) *	2004-06-09	2005-12-15	Allergan, Inc.	Pharmaceutical compositions comprising cyclosporins
EP2444071A1 (en) *	2004-09-27	2012-04-25	Sigmoid Pharma Limited	Minicapsule formulations
US7378391B2 (en) *	2004-09-29	2008-05-27	Amr Technology, Inc.	Cyclosporin alkyne analogues and their pharmaceutical uses
WO2006039164A2 (en) *	2004-09-29	2006-04-13	Amr Technology, Inc.	Novel cyclosporin analogues and their pharmaceutical uses
WO2006041631A2 (en) *	2004-10-06	2006-04-20	Amr Technology, Inc.	Novel cyclosporin alkynes and their utility as pharmaceutical agents
US7151085B2 (en) *	2004-11-15	2006-12-19	Allergan, Inc.	Therapeutic methods using cyclosporine components
US7135455B2 (en) *	2004-11-15	2006-11-14	Allergan, Inc	Methods for the therapeutic use of cyclosporine components
US20060148686A1 (en) *	2004-12-30	2006-07-06	Bausch & Lomb Incorporated	Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
JP4974903B2 (ja)	2005-02-09	2012-07-11	参天製薬株式会社	疾患または状態を処置するための液体処方物
AU2006270041B2 (en)	2005-07-18	2011-08-18	Minu, Llc	Enhanced ocular neuroprotection/neurostimulation
US20070014760A1 (en) *	2005-07-18	2007-01-18	Peyman Gholam A	Enhanced recovery following ocular surgery
AU2006304143A1 (en) *	2005-10-14	2007-04-26	Allergan, Inc.	Prevention and treatment of drug-associated ocular side effects with a cyclosporin
US9839667B2 (en)	2005-10-14	2017-12-12	Allergan, Inc.	Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) *	2005-10-14	2010-06-29	Gregg Feinerman	Prevention and treatment of ocular side effects with a cyclosporin
WO2007056457A2 (en) *	2005-11-09	2007-05-18	Combinatorx, Incorporated	Methods, compositions, and kits for the treatment of medical conditions
WO2007092620A2 (en)	2006-02-09	2007-08-16	Macusight, Inc.	Stable formulations, and methods of their preparation and use
US7655625B2 (en) *	2006-02-13	2010-02-02	Allergan, Inc.	Methods of treating blepharospasm using cyclosporine components
US7557082B2 (en)	2006-03-03	2009-07-07	Allergan, Inc.	Treatment with cyclosporin A
US20070219127A1 (en) *	2006-03-20	2007-09-20	Walt John G	Cyclosporin a compositions
PL2001466T3 (pl)	2006-03-23	2016-06-30	Santen Pharmaceutical Co Ltd	Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
US7696165B2 (en) *	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) *	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US20080146497A1 (en) *	2006-07-25	2008-06-19	Graham Richard S	Cyclosporin Compositions
EP2079456B1 (en)	2007-04-04	2012-12-05	Sigmoid Pharma Limited	Pharmaceutical cyclosporin compositions
CA2686234A1 (en) *	2007-05-04	2008-11-13	Allergan, Inc.	Use of cyclosporines in the treatment of patients with intraocular lenses
US20090081277A1 (en) *	2007-09-21	2009-03-26	Allergan, Inc.	Pharmaceutical formulations and methods for treating ocular conditions
ES2667945T3 (es)	2007-10-08	2018-05-16	Aurinia Pharmaceuticals Inc.	Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
ITMI20080003A1 (it) *	2008-01-02	2009-07-03	Alfredo Pulpito	Composizioni per uso oftalmico
US20100010082A1 (en) *	2008-07-09	2010-01-14	Aspreva International Ltd.	Formulations for treating eye disorders
US9445975B2 (en) *	2008-10-03	2016-09-20	Access Business Group International, Llc	Composition and method for preparing stable unilamellar liposomal suspension
AU2010203607A1 (en)	2009-01-08	2011-07-21	Allergan, Inc.	Cyclosporine compositions for enhancing nail growth
US20110009339A1 (en) *	2009-04-14	2011-01-13	Allergan, Inc	Method of treating blurred vision and other conditions of the eye with cyclosporin compositions
ES2649112T3 (es)	2009-05-18	2018-01-10	Sigmoid Pharma Limited	Composición que comprende gotas de aceite
US8496976B2 (en)	2009-06-05	2013-07-30	Allergan, Inc.	Artificial tears and therapeutic uses
EP2440185B1 (en) *	2009-06-09	2015-04-08	Aurinia Pharmaceuticals Inc.	Topical drug delivery systems for ophthalmic use
CN107582526A (zh)	2009-08-12	2018-01-16	希格默伊德药业有限公司	包含聚合物基质和油相的免疫调节组合物
EP2335735A1 (en)	2009-12-14	2011-06-22	Novaliq GmbH	Pharmaceutical composition for treatment of dry eye syndrome
WO2011079232A1 (en) *	2009-12-23	2011-06-30	Psivida Us, Inc.	Sustained release delivery devices
GB201020032D0 (en)	2010-11-25	2011-01-12	Sigmoid Pharma Ltd	Composition
US8957048B2 (en)	2011-10-06	2015-02-17	Allergan, Inc.	Compositions for the treatment of dry eye
JP6363506B2 (ja)	2011-11-15	2018-07-25	アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ	シクロスポリンａ２型の懸濁剤
RU2639393C2 (ru)	2011-11-15	2017-12-21	Аллерган, Инк.	Состав пролонгированного действия циклоспорина формы 2
ES2666191T3 (es)	2011-11-15	2018-05-03	Allergan, Inc.	Un proceso para la cristalización de la forma 2 de la ciclosporina A
US9907826B2 (en)	2011-12-07	2018-03-06	Allergan, Inc.	Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US20130266615A1 (en) *	2012-04-10	2013-10-10	Bin Wu	Non-immunogenic delivery vehicle for beta-, gamma-, and delta-tocopherols and methods of using and making same
CA2871070C (en) *	2012-04-20	2024-01-02	Howard University	Method of treating an ocular disease and compositions effective for treating an ocular disease
GB201212010D0 (en)	2012-07-05	2012-08-22	Sigmoid Pharma Ltd	Formulations
GB201319791D0 (en)	2013-11-08	2013-12-25	Sigmoid Pharma Ltd	Formulations
EP3881829A1 (en)	2014-11-07	2021-09-22	Sublimity Therapeutics Limited	Compositions comprising cyclosporin
NZ732058A (en)	2014-11-25	2023-06-30	Allergan Inc	Stabilized omega-3 ophthalmic compositions
US9820954B2 (en)	2015-08-19	2017-11-21	Jenivision Inc.	Quantitative peri-orbital application of ophthalmology drugs
US20190224275A1 (en)	2017-05-12	2019-07-25	Aurinia Pharmaceuticals Inc.	Protocol for treatment of lupus nephritis
JP7598699B2 (ja) *	2017-06-01	2024-12-12	ロート製薬株式会社	視覚機能の再活性化用眼科組成物
EP4346720A4 (en)	2021-05-28	2025-01-01	Sight Sciences, Inc.	INTRAOCULAR DEVICES, SYSTEMS AND METHODS
WO2025248489A1 (en) *	2024-05-29	2025-12-04	Sight Sciences, Inc.	Bio-erodible ocular implants for treatment of conditions of the eye

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3608073A (en) *	1968-07-16	1971-09-21	Barnes Hind Pharm Inc	Emulsion of pilocarpine for ophthalmic use
US4210581A (en) *	1975-11-04	1980-07-01	Sandoz Ltd.	Organic compounds
CH614931A5 (da) *	1975-11-04	1979-12-28	Sandoz Ag
US4117118A (en) *	1976-04-09	1978-09-26	Sandoz Ltd.	Organic compounds
US4115544A (en) *	1976-08-18	1978-09-19	Alza Corporation	Ocular system made of bioerodible esters having linear ether
DE2819094A1 (de) *	1977-05-10	1978-11-23	Sandoz Ag	Cyclosporin-derivate, ihre verwendung und herstellung
FI65914C (fi) *	1978-03-07	1984-08-10	Sandoz Ag	Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
US4215199A (en) *	1978-06-05	1980-07-29	Sandoz Ltd.	Antibiotic production
SE448386B (sv) *	1978-10-18	1987-02-16	Sandoz Ag	Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
US4396542A (en) *	1980-02-14	1983-08-02	Sandoz Ltd.	Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
EP0034567B1 (en) *	1980-02-14	1984-11-07	Sandoz Ag	A method for the total synthesis of cyclosporins and novel cyclosporins
DE3260468D1 (en) *	1981-01-09	1984-09-06	Sandoz Ag	Novel cyclosporins
WO1983001252A1 (en) *	1981-10-09	1983-04-14	Hakanson, Rolf	A drug based on a substance p antagonist
WO1984004680A1 (en) *	1983-05-25	1984-12-06	Alcon Lab Inc	Ophthalmic gel
US4708861A (en) *	1984-02-15	1987-11-24	The Liposome Company, Inc.	Liposome-gel compositions
CH667274A5 (de) *	1984-03-23	1988-09-30	Sandoz Ag	Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
US4963367A (en) *	1984-04-27	1990-10-16	Medaphore, Inc.	Drug delivery compositions and methods
EP0170623B1 (en) *	1984-08-02	1990-11-28	Sandoz Ag	Novel pharmaceutical use of (nva)2-cyclosporine
GB8422253D0 (en) *	1984-09-04	1984-10-10	Sandoz Ltd	Organic compounds
EP0194972B1 (en) *	1985-03-11	1992-07-29	Sandoz Ag	Novel cyclosporins
US4649047A (en) *	1985-03-19	1987-03-10	University Of Georgia Research Foundation, Inc.	Ophthalmic treatment by topical administration of cyclosporin
JPS61249918A (ja) *	1985-04-26	1986-11-07	Yutaka Mizushima	点眼剤
US4745100A (en) *	1985-05-14	1988-05-17	Eye Research Institute Of Retina Foundation	Stimulation of tear secretion
US4861580A (en) *	1985-10-15	1989-08-29	The Liposome Company, Inc.	Composition using salt form of organic acid derivative of alpha-tocopheral
GB8528032D0 (en) *	1985-11-13	1985-12-18	Ici Plc	Ocular treatment
US4923699A (en) *	1988-06-03	1990-05-08	Kaufman Herbert E	Eye treatment suspension

1988
- 1988-08-31 KR KR1019890700680A patent/KR920003601B1/ko not_active Expired
- 1988-08-31 EP EP88908033A patent/EP0391909B1/en not_active Expired - Lifetime
- 1988-08-31 AT AT88908033T patent/ATE109970T1/de not_active IP Right Cessation
- 1988-08-31 DE DE3851152T patent/DE3851152T2/de not_active Expired - Lifetime
- 1988-08-31 WO PCT/US1988/003039 patent/WO1989001772A1/en not_active Ceased
- 1988-08-31 JP JP63507463A patent/JPH0667850B2/ja not_active Expired - Lifetime
- 1988-09-02 IE IE266388A patent/IE65582B1/en not_active IP Right Cessation
- 1988-09-02 ES ES8802718A patent/ES2012116A6/es not_active Expired - Lifetime
- 1988-09-02 PH PH37495A patent/PH24814A/en unknown
- 1988-09-05 GR GR880100578A patent/GR1000558B/el not_active IP Right Cessation
1990
- 1990-02-06 US US07/474,683 patent/US5411952A/en not_active Expired - Lifetime
- 1990-03-01 DK DK054390A patent/DK54390A/da not_active Application Discontinuation

Also Published As

Publication number	Publication date
GR1000558B (el)	1992-08-26
EP0391909B1 (en)	1994-08-17
KR890701084A (ko)	1989-12-19
KR920003601B1 (ko)	1992-05-04
JPH03503159A (ja)	1991-07-18
IE65582B1 (en)	1995-11-01
PH24814A (en)	1990-10-30
DK54390D0 (da)	1990-03-01
DE3851152T2 (de)	1995-01-26
IE882663L (en)	1989-03-03
DE3851152D1 (de)	1994-09-22
GR880100578A (en)	1989-06-22
US5411952A (en)	1995-05-02
JPH0667850B2 (ja)	1994-08-31
ES2012116A6 (es)	1990-03-01
ATE109970T1 (de)	1994-09-15
EP0391909A1 (en)	1990-10-17
WO1989001772A1 (en)	1989-03-09

Legal Events

Date	Code	Title	Description
2000-04-10	AHB	Application shelved due to non-payment

Publication	Publication Date	Title
DK54390D0 (da)	1990-03-01	Okularcyklosporinpraeparat
CA1303503C (en)	1992-06-16	Ophthalmic solution comprising iodine-polyvinylpyrrolidone complex
MX9702349A (es)	1997-06-28	Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
AU690377B2 (en)	1998-04-23	Application of superoxide dismutase in liposomes
CA2059403A1 (en)	1992-07-16	Use of Carrageenans in Topical Ophthalmic Compositions
EP1225168A3 (en)	2003-03-26	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
ATE165237T1 (de)	1998-05-15	Starkschaumende orale zusammensetzung
IE831611L (en)	1984-01-13	Topical anti-inflammatory compositions
IE811654L (en)	1982-02-01	Ophthalmic composition
GB2075341B (en)	1983-12-14	Pharmaceutical compositions
US4197301A (en)	1980-04-08	Topical ophthalmic use of Prazosin
DE3167210D1 (en)	1984-12-20	Pharmaceutical composition
KR880007068A (ko)	1988-08-26	13-시스 레티노산의 용도
KR950000138A (ko)	1995-01-03	안(眼)국소용 조성물
KR880001290A (ko)	1988-04-22	β-차단제 및 필로카르핀-함유 제제
KR950702422A (ko)	1995-07-29	(에스)-티몰롤 헤미하이드레이트를 함유하는 안약 국소 조성물(ophthalmic topical composition containing (s)-timolol hemihydrate)
RU95106983A (ru)	1997-11-27	Офтальмологический состав, способ его получения и средство для офтальмологического состава
CA2015427A1 (en)	1990-10-26	Pharmaceutical composition for topical ophthalmic use having improved local tolerability
IT1241928B (it)	1994-02-01	Composizione oftalmica per l'uso nel mantenimento della midriasi oculare
KeeS	1996	Johnson Syndrome are two disorders usually described as mucin deficiency dry eye syndromes. A classic example of mucin deficiency caused by degeneration or loss of goblet cells is hypo-vitaminosis A. This can be induced experimentally in laboratory animals and is found endemically in developing countries. It appears that Vitamin A is necessary for maturation of goblet cells, and that it
MY100229A (en)	1990-05-29	Topical anti-inflammatory compositions.
IT1257884B (it)	1996-02-16	Formulazioni farmaceutiche per il trattamento di malattie periferiche vascolari a base di vincamina o di un suo sale farmaceuticamente accettabile.